RxDoctor Payments Data

Harshal Desai, MD

Internal Medicine · Houston, TXNPI 1578097622

Payments from drug & device makers

$8,009in general payments, 2019–2025

Across 206 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AstraZeneca$2K
  • Bayer$525
  • Travere Therapeutics, Inc.$446
  • Otsuka America Pharmaceutical, Inc.$384
  • GSK$214
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1,40017%
  • Food & beverage$6,15177%
  • Education$4586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,009 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,639
Medicare patients
308
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase32$891,893
JynarqueTolvaptan14$270,184
KerendiaFinerenone78$69,939
JardianceEmpagliflozin51$68,713
FarxigaDapagliflozin Propanediol59$58,086
LokelmaSodium Zirconium Cyclosilicate46$47,635
VeltassaPatiromer Calcium Sorbitex19$34,526
OzempicSemaglutide18$23,049
TrulicityDulaglutide11$18,904
Sevelamer Carbonate35$8,621
Nifedipine ErNifedipine127$2,825
Sodium Polystyrene Sulfonate11$2,541
Hydralazine Hcl111$2,257
Calcium Acetate20$1,968
Clonidine13$1,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$3,651$891,89332 claims
Otsuka America Pharmaceutical, Inc.Jynarque$384$270,18414 claims
AstraZenecaFarxiga, Lokelma$1,734$105,722105 claims
BayerKerendia$525$69,93978 claims
Boehringer IngelheimJardiance$75$68,71351 claims
Novo NordiskOzempic$181$23,04918 claims
ANI Pharmaceuticals, Inc.Valsartan$57$1,28942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →